Community/Retail

A recently-published study evaluated increasing concerns that plaque psoriasis medications may trigger inflammatory bowel disease (IBD).

It is the first treatment approved in the United States for the treatment of Chagas disease.

Officials with the FDA have announced the approval of Vabomere (Rempex) for the treatment of complicated urinary tract infections (cUTI).

Boehringer said they also plan to seek approval for an auto-injector of the biosimilar to expand options for patients.

There are several roles pharmacists can play in managing patients with cardiovascular disease, including blood pressure and medication monitoring.

The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of care.

John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology, discusses the vexing problem of patients who fail to fill or take recommended medications.

Kite's most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the US FDA, and is expected to be a treatment option for refractory aggressive non-Hodgkin lymphoma,

John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology, discusses the digital innovations that will have major effects on the cardiovascular field in years to come.

In this clip, Deepak Bhatt, MD, discusses the results of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial, presented at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.

In this clip, Steven Nissen, MD, of the Cleveland Clinic discusses some new data on anti-inflammatories and cardiovascular events that were presented this week at the European Society of Cardiology.

Hurricane season is here, and it is important to be prepared.

The program is a combination of research, health care services, and community involvement in harm reduction strategies.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Officials with the FDA have approved a new indication for liraglutide (Victoza, Novo Nordisk).

Officials with the CDC have published recommendations from the Advisory Committee on Immunization Practices (ACIP) for the prevention and control of seasonal influenza with vaccines for the 2017-2018 season.

Without the nasal spray as an immunization option for influenza, vaccination rates in children dropped in the 2016-2017 season, according to new data published in Vaccine.

This may be the first drug shown to reduce mortality in the HFpEF population in the United States but will hopefully not be the last.

This nontraditional opportunity bridges business and health care. Here is a look at a unique, client-facing role within this niche.

It is important to align pharmacy services with changes in the population.

A number of landmark clinical studies on lipid lowering and cardiovascular health have been published, shaping how patients are treated.

The thing is, you still may get sick after getting the flu because there are other things such as the common cold that might cross your path.

For HIV-mixed status couples attempting conception, prior effective antiretroviral therapy (ART) can profoundly reduce the risk of sexual transmission of the disease, according to a report published in the Morbidity and Mortality Weekly Report.

This testing has a positive clinical and therapeutic impact on dosage requirements and ethical considerations.

Here is the 411 on this organization, which offers programs to help consumers better understand their medications.

August is National Immunization Awareness Month. As community pharmacies gear up for flu season, here is how to inform, educate and support patients.

The truth is it’s one thing to hate your job, but it’s another thing completely to hate your job and do nothing about it.

For the first time, epilepsy rate estimates have been available for every state, totaling in at least 3.4 million individuals living with the disorder.